分类： health

BUNIA, Democratic Republic of Congo — A growing wave of community distrust around the ongoing Bundibugyo Ebola outbreak in eastern Congo has boiled over into a second arson attack on a public health facility in less than a week, triggering a dangerous escape of infected patients and deepening concerns over virus containment efforts. Local hospital director Dr. Richard Lokudi, head of Mongbwalu General Reference Hospital, confirmed to the Associated Press that unidentified assailants targeted an MSF (Doctors Without Borders) isolation tent late Friday. The tent had been purpose-built to house both confirmed and suspected cases of the rare Bundibugyo strain of Ebola, which is currently driving the outbreak centered on the Mongbwalu area.

In the wake of the attack, 18 patients being monitored for possible Ebola infection fled the facility into the surrounding community, a development that public health officials warn drastically elevates transmission risks. “We strongly condemn this act, as it caused panic among the staff of the Mongbwalu Referral Hospital and also resulted in the escape of 18 suspected cases into the community,” Lokudi said. The attack marks the second targeting of Ebola response infrastructure in the region this week: just two days prior, a separate treatment center in nearby Rwampara was burned to the ground by community members after authorities blocked family members from recovering the body of a local man who had died from the virus.

This tension stems from a critical point of conflict between public health guidelines and local cultural practices: Ebola corpses are extremely contagious, and traditional funeral gatherings and body preparation are among the most common pathways for large-scale secondary spread. To curb transmission, authorities manage burials of confirmed and suspected Ebola victims whenever possible, a policy that frequently sparks pushback from grieving family and community members.

As community tensions mount, regional authorities have implemented strict new public health measures to slow the outbreak. On Friday, officials in northeastern Congo announced a ban on funeral wakes and all public gatherings of more than 50 people. The World Health Organization has also upgraded its risk assessment for the outbreak, raising the domestic risk level from “high” to “very high” while noting that the risk of global spread remains low at this stage.

As of Friday, WHO Director-General Tedros Adhanom Ghebreyesus reported that 82 confirmed cases and seven confirmed deaths have been recorded, but he warned that the actual size of the outbreak is far larger than official confirmed counts. Currently, surveillance systems are tracking 750 additional suspected cases and 175 suspected deaths, numbers expected to rise as public health workers expand monitoring across the region.

A unique factor complicating the response to this outbreak is the lack of an approved vaccine for the Bundibugyo strain. The virus spread undetected for weeks across Ituri province after the first recorded death, when initial testing incorrectly targeted the more common Zaire Ebola strain and returned negative results, delaying the activation of a full response. Most recently, the revelation that three International Federation of Red Cross and Red Crescent Societies volunteers died from the virus in Mongbwalu after contracting it during a non-Ebola body management mission on March 27 has pushed back the estimated timeline of the outbreak. Previously, the first confirmed death was dated to late April in Bunia, Ituri’s capital.

Top African public health leaders have emphasized that repairing community trust is a core component of any effective response. “A response to the outbreak must include building trust with communities,” said Dr. Jean Kaseya, director-general of the Africa Centers for Disease Control and Prevention. On Saturday, a burial for Ebola victims in Bunia proceeded only under heavy armed security, a stark indicator of the ongoing friction between response teams and local communities. The Red Cross has confirmed that three of its volunteers have died from the virus linked to this outbreak, marking a major loss for the humanitarian effort working to contain the spread.

On the morning of May 1, as South Africa paused to observe the Labor Day public holiday, leading South African infectious disease specialist Lucille Blumberg logged into her work email and encountered an urgent alert that would launch a rapid, cross-continental disease investigation. The message came from a public health colleague based in the United Kingdom, who was monitoring disease activity across remote South Atlantic British overseas territories. It detailed a worrying situation: a passenger from a Dutch cruise ship sailing thousands of miles across the Atlantic had been medically evacuated and admitted to a Johannesburg hospital for suspected pneumonia, with multiple other passengers and crew on the vessel already showing symptoms of illness.

The passenger had been evacuated from the ship off Ascension Island, one of the British territories the UK-based colleague monitors, and Blumberg was asked to lead the follow-up investigation into the mysterious illness. Within hours, Blumberg and a team of specialists from South Africa’s National Institute for Communicable Diseases were mobilized, putting aside holiday plans to race against the clock to identify the cause of the growing outbreak on board the MV Hondius cruise liner.

“Even though it was a public holiday, we moved, we moved really fast,” Blumberg recalled in an interview with the Associated Press. “It was busy. There were many conversations. There were online discussions, and there was laboratory testing happening at the time.” In what would become a defining display of global public health collaboration, the team achieved a breakthrough in less than 24 hours, confirming the evacuated patient was infected with hantavirus, a rare pathogen carried and spread by rodents.

### A Methodical Process of Elimination
When the elderly British patient first arrived at the private Johannesburg hospital, he was in critical condition, and clinicians had no clear answer for what was causing his severe respiratory illness. By the time he was evacuated from the ship, two elderly Dutch passengers who had fallen ill on the cruise had already died, but the full scope of the outbreak had not yet come into focus. Health authorities on Ascension Island had only reported a cluster of pneumonia-like illnesses to the World Health Organization (WHO) without identifying a root cause.

Initially, Blumberg and her team prioritized the most likely causes of a respiratory outbreak on a cruise ship. Their first working theories were Legionella, a common bacterium linked to cruise ship and hotel pneumonia outbreaks that causes Legionnaires’ disease, and avian influenza, since the ship’s itinerary included stops at South Atlantic islands where bird flu is well documented. “Legionella is well described in outbreaks in hotels and on cruise ships, and influenza certainly is. These people had visited islands where avian influenza is well documented,” Blumberg explained.

Initial tests for both pathogens came back negative. The team ran a full panel of tests for dozens of other common respiratory illnesses, and all of those also returned negative results. It was only when the team shifted their focus to the ship’s full itinerary and the profile of passengers that a new lead emerged: the MV Hondius had sailed from Argentina, and most passengers on board were avid bird watchers who had spent time exploring remote areas of South America that are home to large rodent populations.

### Global Collaboration Drives Rapid Diagnosis
The new clue led the South African team to test for a less common but well-documented pathogen in southern South America: hantavirus, specifically the Andes strain that is endemic to parts of Chile and Argentina. Their work was greatly accelerated by close collaboration with hantavirus specialists based in South America and the United States, with the WHO coordinating cross-border communication between experts. “You can get onto a Zoom online and ask your questions and get advice. This is not something every day. So that was quite extraordinary,” Blumberg noted of the international cooperation.

By Saturday morning, just two days after the initial alert, Blumberg contacted the director of South Africa’s only laboratory equipped to test for hantavirus. Within hours, the lab director had mobilized her team on the weekend to process the samples. “I said, we want to do hanta, and she said, ‘yeah, I’m coming,’” Blumberg recalled. That same afternoon, initial tests on the evacuated patient’s blood samples came back positive for hantavirus. The team ran a second round of confirmatory testing to rule out error, and the positive result was upheld.

### Confirmation Paves the Way for Targeted Outbreak Response
The positive diagnosis, which also confirmed the pathogen was the Andes hantavirus strain, allowed the WHO to immediately alert the cruise ship leadership and formally declare a hantavirus outbreak on board. Unlike most hantavirus strains, which cannot spread easily between humans, the Andes variant can pass from person to person, making rapid identification critical to implementing appropriate safety measures. After the diagnosis, Blumberg’s team also moved quickly to test tissue samples from a deceased Dutch passenger, one of the two who had died earlier in the outbreak. The woman had disembarked at St. Helena to accompany her husband’s remains before traveling to South Africa where she later died, and her posthumous test also returned positive for hantavirus.

“It was a bit of a wow moment,” Blumberg said. “And at least once you know what you’re dealing with, it’s much easier to respond.” As of the latest update from South Africa’s health ministry, the British patient who was the first confirmed case is now recovering in hospital and showing steady improvement. Meanwhile, the MV Hondius has completed its journey to its home port of Rotterdam in the Netherlands, where the vessel was thoroughly disinfected and all remaining crew have disembarked for monitoring.

With 25 years of experience responding to disease outbreaks around the world, Blumberg framed the rapid identification of the cruise ship hantavirus as a case study in effective public health practice. “I’ve been doing outbreaks for 25 years. That’s what we do. We do them every day,” she said. “I think the important thing was to respond immediately to a question that clearly was urgent and then to take it from there.”

More than a decade after West Africa suffered the deadliest Ebola epidemic in recorded history, a new outbreak in the eastern Democratic Republic of the Congo has stirred traumatic memories for survivors of the earlier crisis, while forcing global health experts to confront gaps in preparedness for rare, untreatable strains of the virus.

Patrick Faley, a Liberian Ebola survivor who lost his four-year-old son to the disease during the 2013–2016 West African outbreak that killed over 11,000 people across Guinea, Liberia and Sierra Leone, says images of medics scrambling to contain the DR Congo outbreak have brought back haunting recollections of loss and chaos. “I saw the burial team taking eight of them,” Faley recalled. “I made new friends although they ended up dying. I was the only person that was left there.”

Faley was recruited as a community health volunteer by Liberia’s Ministry of Health at the height of the West African epidemic, tasked with traveling between rural villages to educate locals on how Ebola spreads through direct contact with bodily fluids, discourage unsafe traditional practices like handshakes and ritual washing of deceased bodies, and dispel dangerous misinformation about the virus. His own infection came after he set aside safety guidance to comfort grieving community members at a colleague’s Ebola funeral: “You have to shake hands; you have to hug people. Forgetting to know that we have a crisis, an emergency crisis in our country.”

Three days after the funeral, Faley fell ill, transforming from a frontline outreach worker to a patient in an overcrowded Monrovia treatment ward, where he watched dozens of patients die waiting for care. He survived the infection, but his wife and young son later contracted the virus. While his wife recovered, four-year-old Momo did not survive.

Today, the lessons learned from Faley’s experience and the broader West African outbreak are shaping the public health response to the new DR Congo outbreak, where the World Health Organization (WHO) has confirmed over 170 deaths so far. One key change adopted from past outbreaks is an immediate ban on traditional funerals for suspected Ebola cases to cut transmission chains — but the policy has already sparked community unrest. Last Thursday, a crowd angry over authorities’ refusal to release a body for burial set fire to part of a hospital near the outbreak epicenter in Bunia.

Dr. Patrick Otim, the WHO’s Africa area manager, emphasized that integrating past lessons into the current response is non-negotiable, and that community buy-in is as critical as medical infrastructure. “One of the biggest lessons from the West Africa outbreak and previous Ebola outbreaks in DRC is that speed matters,” Otim explained. “Early delays in detecting cases, isolating patients and engaging communities can allow transmission chains to expand very quickly.” He added that outbreaks cannot be controlled by medical intervention alone: “Community trust is essential. Safe and dignified burials, local leadership engagement and clear communication are just as important as laboratories and treatment centers.”

This outbreak marks the 17th Ebola event recorded in DR Congo since the virus was first identified in 1976, but it carries unique challenges: it is only the third global outbreak of the rare Bundibugyo Ebola strain, a variant that circulates far less often than the common Zaire strain. Unlike the 2013–2016 West African outbreak, which was eventually curbed with the first approved Ebola vaccine Ervebo, no approved vaccine or specific treatment exists for Bundibugyo.

Professor Thomas Geisbert, a leading Ebola researcher at the University of Texas Medical Branch and co-inventor of Ervebo, explained that the genetic makeup of Bundibugyo differs from Zaire by roughly 30%, rendering existing stockpiled vaccines ineffective. “Just because a vaccine works against one particular type of a virus doesn’t mean it’s going to work against another one,” he said. Ervebo remains the only Ebola vaccine currently available in the global emergency stockpile.

Developing new vaccines is an expensive, time-consuming process that has long been overlooked by profit-driven pharmaceutical companies, Geisbert noted. He and other researchers have already made progress on a Bundibugyo vaccine built on Ervebo’s existing framework, with preclinical trials in non-human primates showing 83% protection. However, the candidate has not yet moved to human testing. Geisbert estimates that moving a vaccine from laboratory development to full-scale deployment can cost more than $1 billion, a price tag that has so far discouraged private sector investment. Teams at the University of Oxford have also announced they are developing a candidate that could be ready for human trials within two to three months, and the WHO says a fully tested, deployable vaccine could take up to nine months to deliver.

Kenyan biochemistry professor Wallace Bulimo of the University of Nairobi said the current outbreak exposes a long-standing failure to prioritize research on less common Ebola strains, which were first identified as a distinct variant in 2007. “Why is it that we have not actually done a lot of work on this virus? And yet we knew it was there,” Bulimo said. “It was first discovered in 2007, so we should have actually never ignored it.”

Faley, who has experienced first-hand the fallout of mismanaged community outreach, warns response teams against openly telling locals that the current outbreak has no cure. Doing so, he argues, will discourage sick people from seeking treatment and fuel stigma, as communities believe seeking care is a death sentence. He also cautions against the common pitfalls of a sudden influx of international aid: large numbers of foreign responders can stoke fear and distrust in local communities, which played a role in slowing the West African response early on. Currently, tons of aid have been shipped to the outbreak epicenter in Ituri province, and multiple international medical and UN agencies are preparing to deploy support teams.

Unlike the early days of the West African outbreak, DR Congo has built up one of the world’s most experienced workforces for Ebola response over the past decade, having managed 16 prior outbreaks. Otim stressed that the Congolese government is leading the current response, and the country has built robust expertise in everything from case detection to outbreak coordination. The biggest challenges do not stem from a lack of experience, he said — instead, they come from the region’s difficult operating environment: long-standing insecurity from armed groups, widespread population displacement, crumbling infrastructure, and constant cross-population movement all make containment far more complex.

Experts warn the outbreak may already be larger than official counts show, as confirmation of the first case took three weeks: the initial patient, a nurse, developed symptoms on April 24, but the outbreak was not confirmed until mid-May. While the situation remains serious, there are small points of cautious optimism: the historical case fatality rate for Bundibugyo is roughly 30%, lower than many other Ebola strains. Still, Geisbert noted that Bundibugyo has a longer incubation period than other variants, which means infected people can unknowingly spread the virus in communities for longer before developing symptoms.

On a more encouraging note, the WHO plans to prioritize experimental use of the antiviral drug Obladesivir, which was developed during the COVID-19 pandemic, under strict clinical protocols. Researchers hope the drug may prevent infection in people who have been exposed to confirmed Ebola cases.

For his part, Faley says he stands ready to support affected communities in DR Congo, drawing on his own experience as a survivor to help people navigate the trauma of the outbreak. “Our arms are open as Liberians,” he said. “Our arms are open in order to help our colleagues who will be surviving, to give them a proper perspective, what it means to survive Ebola. I will always be here to advocate for survival.”

The World Health Organization has escalated its public health risk assessment for the ongoing Ebola outbreak in the Democratic Republic of the Congo, raising the national-level threat from “high” to “very high” in an official update released Friday.

During a press briefing in Geneva, WHO Director-General Dr. Tedros Adhanom Ghebreyesus outlined the tiered risk framework: while the outbreak poses a very high danger within DR Congo’s borders, it carries a high risk for the broader African region, and remains a low risk at the global scale. The WHO had already declared a Public Health Emergency of International Concern (PHEIC) for the outbreak earlier this week, though it stopped short of classifying the event as a pandemic.

The outbreak is driven by Bundibugyo, an uncommon strain of Ebola that currently has no licensed, widely available vaccine, and claims the lives of roughly one out of every three people it infects. As of the latest update, the outbreak has recorded 750 suspected cases and 177 suspected deaths across DR Congo, with 82 confirmed cases and seven confirmed fatalities. The virus has already spread beyond DR Congo’s borders: neighboring Uganda has reported two confirmed cases, linked to travelers from the affected DR Congo region, including one death. WHO officials noted that the situation in Uganda currently remains stable.

Unlike more common Ebola variants, the rarity of the Bundibugyo strain has left public health responders with far fewer established countermeasures to slow transmission, even though it is slightly less deadly than other Ebola types. Like all Ebola viruses, Bundibugyo originates in wild animal populations, most commonly fruit bats, and typically spills over to humans when individuals handle or consume contaminated bushmeat.

Compounding the public health challenge, persistent violence and instability in the conflict-affected eastern region of DR Congo has severely hampered outbreak response efforts. Dr. Tedros emphasized that building community trust is critical to containing the spread, noting a recent incident where angry relatives set fire to a local hospital after health workers declined to release an Ebola patient’s body over fears of viral contamination.

Amid the growing risk, research teams are racing to develop targeted vaccines for the strain. A team of scientists at the University of Oxford in the United Kingdom is advancing a candidate vaccine that could be ready for human clinical trials in as little as two to three months. There is no guarantee the candidate will prove effective, however, as rigorous preclinical animal testing and human trials will be required to confirm safety and efficacy. A second experimental vaccine candidate is also in development, but that candidate is not expected to be ready for testing for six to nine months.

A rapidly escalating Ebola outbreak in the Democratic Republic of Congo (DRC), driven by a rare, untreatable strain of the virus, has spurred urgent vaccine development work from a team of researchers at the University of Oxford, with the candidate potentially ready for field deployment within months.

The ongoing outbreak, centered in northeastern DRC, has already been linked to 750 suspected cases and 175 confirmed deaths, according to latest outbreak tracking data. The pathogen at the center of the crisis is Bundibugyo, an understudied Ebola species that has only caused two recorded outbreaks in the last 20 years and has no licensed, proven vaccine currently available. The virus kills roughly one-third of all people it infects, making swift containment a top global health priority.

In response to the crisis, the World Health Organization (WHO) has upgraded the risk level of the outbreak from “high” to “very high” within DRC, with regional risk across central Africa also elevated to “high.” International risk remains low, however, and the WHO declared a Public Health Emergency of International Concern (PHEIC) over the outbreak over the weekend, explicitly noting that the event does not rise to the level of a pandemic.

Oxford’s vaccine candidate leverages the same ChAdOx1 platform the university’s vaccine group refined during the global COVID-19 pandemic – a flexible, easily adaptable genetic vaccine technology that can be rapidly modified to target new pathogens. During the COVID response, the platform was loaded with coronavirus genetic material; for this Ebola candidate, it has been reconfigured to carry genetic code from the Bundibugyo strain.

The platform relies on a modified chimpanzee common cold virus, genetically edited to be safe for human use, that delivers Bundibugyo genetic material to human cells. This trains the immune system to recognize and neutralize the actual Ebola virus if exposure occurs, without causing Ebola infection or symptomatic disease. Preclinical animal testing for the new candidate is already underway at Oxford’s facilities, and the Serum Institute of India has been pre-positioned to scale up mass manufacturing as soon as the university provides clinical-grade vaccine material.

Professor Sarah Lambe, head of vaccine immunology at the Oxford Vaccine Group, emphasized that speed is the top priority for the project. “People are worried about this outbreak, generally, you prepare for the worst case scenario – hopefully contact tracing and quarantine is all that’s needed, but we can’t take our foot off the gas,” Lambe told BBC News. Once the research team delivers initial starting material to the Serum Institute, Lambe noted that the manufacturer can ramp up production both quickly and at large scale. The WHO projects that the candidate could be ready for human clinical trials in affected regions within two to three months.

This outbreak poses unique challenges to global health responders because of the rarity of the Bundibugyo strain. Of the six known Ebola species, only three are known to cause large human outbreaks, and Bundibugyo had not been detected in more than a decade prior to this event – its last outbreak occurred in DRC in 2012, following an initial 2007 outbreak in Uganda. While existing effective vaccines are available for the more common Zaire Ebola strain, none have been approved for Bundibugyo. A separate experimental Bundibugyo candidate is also in development, but that effort is not expected to produce testable doses for another six to nine months, making Oxford’s accelerated timeline a critical asset for outbreak response.

If authorized, the vaccine will not be deployed in mass public vaccination campaigns like COVID-19 vaccines. Instead, it will be used in the targeted ring vaccination strategy standard for Ebola outbreaks, which prioritizes immunization for people at highest exposure risk: close contacts of confirmed cases, and frontline healthcare workers treating infected patients. The Oxford team had already been working on related vaccine candidates for other dangerous filoviruses, including Sudan ebolavirus and Marburg virus, prior to this outbreak, allowing them to adapt their work rapidly to address the new Bundibugyo emergency.

GENEVA, Switzerland – In a stark update delivered to reporters on Friday, World Health Organization Director-General Tedros Adhanom Ghebreyesus announced a troubling escalation of the ongoing Ebola outbreak in the Democratic Republic of the Congo, raising the national risk assessment from high to the most severe tier of “very high” amid evidence of accelerating transmission.

Tedros clarified that while the domestic risk has worsened, the threat of regional spillover still holds at a high level, and the global risk of widespread Ebola spread remains categorized as low. Official counts place the number of confirmed cases at 82, with seven confirmed fatalities recorded so far, but the WHO leader emphasized that the true scale of the epidemic far outpaces these confirmed numbers. Currently, more than 750 additional cases are classified as suspected, with 177 suspected deaths linked to the outbreak across affected areas of the country.

Neighboring Uganda has so far avoided widespread community transmission, with the situation there remaining classified as stable. Two confirmed Ebola cases have been recorded in the country, both tied to travel from the DRC, and one of those patients has died.

The rapidly deteriorating situation has prompted immediate action from the global humanitarian community. Earlier on Friday, the United Nations confirmed it had disbursed $60 million from its Central Emergency Response Fund, a reserve pool of emergency funding designated to speed up outbreak response efforts across the DRC and the broader Great Lakes region. The United States also announced a pledge of $23 million in new funding to support response operations in both the DRC and Uganda, alongside a plan to finance the construction of up to 50 new Ebola treatment clinics across affected zones in both countries.

Notably, Ugandan health authorities have publicly stated that they have no knowledge of planned U.S.-funded treatment centers being established within their borders, creating a small point of discrepancy in the announcement of international support.

Nestled in the heart of East Africa, the “Land of a Thousand Hills” Rwanda draws visitors with its sweeping green mountain slopes, but this same dramatic terrain creates unique public health challenges for its population. For millions of Rwandans, daily life requires traversing steep, winding mountain paths for hours at a time, a routine that gradually wears down joints, muscles and musculoskeletal health over years.